🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,760 results for “Pharm” Clear

  1. RAVICTI 1.1 g/ml oral liquid

    Pari Pharma GmbH

    Pyruvate dehydrogenase deficiency

    phase 2 small molecule active

    1 trial

  2. RBD3000 Placebo Injection is a clear, colorless sterile solution for subcutaneous injection, which is formulated by 25 mM phosphate buffer

    Lacuna Pharma Pty Ltd

    Mixed Dyslipidemia

    phase 2 small molecule active

    1 trial

  3. RBD4059 injection, Trombyl 75 mg tabletter, The corresponding placebo consist of the 25 mM phosphate buffer solution with 2 µg of vitamin b2 added for colouring purposes only

    Lacuna Pharma Pty Ltd

    Stable Coronary Artery Disease

    phase 2 small molecule active

    1 trial

  4. REC-1245

    RECURSION PHARMACEUTICALS, INC.

    Unresectable

    phase 2 small molecule active

    1 trial

  5. REC-3964

    RECURSION PHARMACEUTICALS, INC.

    Recurrent Clostridioides Difficile Infection

    phase 2 small molecule terminated

    1 trial

  6. REC-4881

    RECURSION PHARMACEUTICALS, INC.

    AXIN1 Gene Mutation

    phase 2 small molecule terminated

    1 trial

  7. REC-4881

    RECURSION PHARMACEUTICALS, INC.

    Familial Adenomatous Polyposis

    phase 2 small molecule active

    1 trial

  8. REC-994

    RECURSION PHARMACEUTICALS, INC.

    Cerebral Cavernous Malformation

    phase 2 small molecule completed

    1 trial

  9. REGN13335, Placebo to REGN13335, REGN13335

    Lacuna Pharma Pty Ltd

    Pulmonary Arterial Hypertension (PAH)

    phase 2 small molecule active

    1 trial

  10. REGN5093

    Lacuna Pharma Pty Ltd

    MET-altered non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  11. REGN7041

    Lacuna Pharma Pty Ltd

    Noninfectious Uveitis

    phase 2 small molecule active

    1 trial

  12. REGN7257

    Lacuna Pharma Pty Ltd

    Severe aplastic anemia (SAA)

    phase 2 small molecule active

    1 trial

  13. REGN7544, REGN7544 Matching Placebo

    Lacuna Pharma Pty Ltd

    Sepsis-Induced Hypotension

    phase 2 small molecule active

    1 trial

  14. REGV131, LNP1265

    Lacuna Pharma Pty Ltd

    Hemophilia B

    phase 2 small molecule active

    1 trial

  15. REKOVELLE 72 micrograms/2.16 mL solution for injection in a pre-filled pen, Pre-filled pen containing 2.16mL solution, subcutaneous injection

    Ferring Pharmaceuticals

    Idiopathic male infertility (including oligoasthenozoospermia).

    phase 2 small molecule active

    1 trial

  16. REZZAYO 200 mg powder for concentrate for solution for infusion

    Mundipharma Pty Limited

    Chronic pulmonary aspergillosis (CPA)

    phase 2 small molecule active

    1 trial

  17. RHB-104

    RedHill Biopharma

    Relapsing Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  18. RIFAMPICIN , TEDIZOLID PHOSPHATE, ISONIAZID , ETHAMBUTOL , PYRAZINAMIDE , RIFAMPICIN, PYRAZINAMIDE AND ISONIAZID, LINEZOLID

    Pari Pharma GmbH

    first suspected infection with Mycobacterium tuberculosis in the lungs

    phase 2 small molecule active

    1 trial

  19. RILPIVIRINE , JNJ-16150108

    Xian-Janssen Pharmaceutical

    HIV-1 Infection

    phase 2 small molecule active

    1 trial

  20. RITUXIMAB, MYCOPHENOLATE MOFETIL, YTB323, FLUDARABINE PHOSPHATE, VOCLOSPORIN, TACROLIMUS, RITUXIMAB, MYCOPHENOLIC ACID, CYCLOPHOSPHAMIDE, TOCILIZUMAB, CYCLOPHOSPHAMIDE, AZATHIOPRINE, BELIMUMAB

    Novartis Pharmaceuticals

    Active, refractory systemic lupus erythematosus (SLE), and active, refractory lupus nephritis (LN)

    phase 2 small molecule active

    1 trial

  21. RO7881583, EMPAGLIFLOZIN, Fulvestrant EVER Pharma 250 mg Injektionslösung in einer Fertigspritze, SACITUZUMAB GOVITECAN , Verzenios 100 mg film-coated tablets, EMPAGLIFLOZIN, PALBOCICLIB, INAVOLISIB, Tecentriq 1 200 mg concentrate for solution for infusion, LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, PALBOCICLIB, PALBOCICLIB, RoActemra 20 mg/mL concentrate for solution for infusion, Kisqali 200 mg film-coated tablets, Verzenios 50 mg film-coated tablets, Tecentriq, Abraxane 5 mg/ml powder for di

    Hoffmann-La Roche

    Metastatic breast cancer, including triple negative breast cancer (TNBC), hormone receptor positive breast cancer (HR+ BC), and HER2 positive and HER2 low breast cancer (HER2+/HER2-low BC)

    phase 2 small molecule active

    1 trial

  22. ROT-TDS, Neupro 8 mg/24 h transdermal patch, Neupro 8 mg/24 h transdermal patch

    Lacuna Pharma Pty Ltd

    Parkinson's disease

    phase 2 small molecule active

    1 trial

  23. RP-A501

    Rocket Pharmaceuticals B.V.

    Danon Disease

    phase 2 gene therapy active

    2 trials

  24. RP-L102

    Rocket Pharmaceuticals B.V.

    Fanconi Anemia Complementation Group A

    phase 2 mab active

    3 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources